Current Gastroenterology Reports

, Volume 8, Issue 2, pp 89–92

Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?

Invited Commentary

DOI: 10.1007/s11894-006-0001-0

Cite this article as:
Derijks, L.J.J. & Hommes, D.W. Curr Gastroenterol Rep (2006) 8: 89. doi:10.1007/s11894-006-0001-0

Conclusions

New strategies for optimizing thiopurine therapy of IBD are promising. TDM and TPMT genotyping seem to be important tools for fine tuning thiopurine therapy, thereby reducing toxicity and improving efficacy. ITPA genotyping and the use of 6-TG in IBD need further research before they can be advocated or banned.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of Clinical PharmacyMáxima Medical CenterMB VeldhovenThe Netherlands

Personalised recommendations